Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF +6.32%66 Equity-to-Asset is 0.95 as of Mar. 2026, which is 23% above its 10-year median of 0.77. GuruFocus rates ZLDPF with a GF Score™ of 66/100 and a GF Value™ of $2,466.28 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Zealand Pharma AS ranks better than 94.12% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Zealand Pharma AS's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $2,238 Mil. Zealand Pharma AS's Total Assets for the quarter that ended in Mar. 2026 was $2,367 Mil.
Therefore, Zealand Pharma AS's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.95.
The historical rank and industry rank for Zealand Pharma AS's Equity-to-Asset or its related term are showing as below:
ZLDPF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23 Med: 0.77 Max: 0.95
Current: 0.95
During the past 13 years, the highest Equity to Asset Ratio of Zealand Pharma AS was 0.95. The lowest was 0.23. And the median was 0.77.
ZLDPF's Equity-to-Asset is ranked better than 94.12% of 1411
companies
in the Biotechnology industry
Industry Median: 0.68
vs ZLDPF: 0.95
Zealand Pharma AS (OTCPK:ZLDPF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zealand Pharma AS Equity-to-Asset Related Terms
Zealand Pharma AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zealand Pharma AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a Equity-to-Asset of 0.95 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zealand Pharma AS and its competitors. This is 23% above median its historical median of 0.77. Over the past decade, Zealand Pharma AS's Equity-to-Asset has ranged from 0.23 to 0.95. According to the industry distribution chart, Zealand Pharma AS ranks #83 out of 1411 companies in the Biotechnology industry, placing it in the top 5.9%.
Is Zealand Pharma AS's Equity-to-Asset too high?
Zealand Pharma AS's current Equity-to-Asset of 0.95 is 23% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Zealand Pharma AS's value of 0.95 is 39.7% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #83 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #83 out of 1411 companies for Equity-to-Asset. This places Zealand Pharma AS in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Zealand Pharma AS's value of 0.95 is 39.7% above this benchmark. Historically, Zealand Pharma AS's own Equity-to-Asset has ranged from 0.23 to 0.95 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.68, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Equity-to-Asset of 0.95 is 39.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Equity-to-Asset is 0.95, which is 23% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,466.28, compared to a current price of $50.50 — trading 98% below its estimated fair value. The current Equity-to-Asset is 0.95, which is 23% above median its 10-year median of 0.77 and 39.7% above the Biotechnology industry median of 0.68. Zealand Pharma AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Equity-to-Asset is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $50.50 is trading 98% below its estimated GF Value™ of $2,466.28.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Equity-to-Asset: 0.95 (23% above median its 10-year median of 0.77)
GF Value™: $2,466.28 vs. price of $50.50 (98% below fair value)
Industry Position: 39.7% above the Biotechnology median (#83 of 1411)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
66GF Score
Get the complete analysis for ZLDPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
